KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket Capitalization

AbCellera Biologics (ABCL) Gross Margin: 2020-2023

Historic Gross Margin for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to 66.23%.

  • AbCellera Biologics' Gross Margin fell 2664.00% to 66.23% in Q4 2023 from the same period last year, while for Dec 2023 it was 62.71%, marking a year-over-year decrease of 2361.00%. This contributed to the annual value of 55.68% for FY2024, which is 703.00% down from last year.
  • Per AbCellera Biologics' latest filing, its Gross Margin stood at 66.23% for Q4 2023, which was up 39.58% from 47.45% recorded in Q3 2023.
  • Over the past 5 years, AbCellera Biologics' Gross Margin peaked at 95.13% during Q2 2020, and registered a low of 47.45% during Q3 2023.
  • Moreover, its 3-year median value for Gross Margin was 84.73% (2021), whereas its average is 78.03%.
  • Its Gross Margin has fluctuated over the past 5 years, first surged by 858bps in 2022, then crashed by 3,772bps in 2023.
  • Over the past 4 years, AbCellera Biologics' Gross Margin (Quarterly) stood at 87.72% in 2020, then slumped by 343bps to 84.29% in 2021, then surged by 858bps to 92.87% in 2022, then plummeted by 2,664bps to 66.23% in 2023.
  • Its last three reported values are 66.23% in Q4 2023, 47.45% for Q3 2023, and 61.80% during Q2 2023.